Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $34.42

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $34.42.

SNDX has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Scotiabank lowered shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and dropped their target price for the company from $36.00 to $23.00 in a research report on Wednesday, January 31st. HC Wainwright reiterated a “buy” rating and set a $41.00 target price on shares of Syndax Pharmaceuticals in a research report on Wednesday, March 27th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research report on Friday, January 19th.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its holdings in Syndax Pharmaceuticals by 97.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock valued at $26,000 after buying an additional 880 shares during the last quarter. CWM LLC raised its holdings in Syndax Pharmaceuticals by 415.3% during the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after buying an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC bought a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $37,000. Quadrant Capital Group LLC raised its holdings in Syndax Pharmaceuticals by 158.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after buying an additional 1,496 shares during the last quarter. Finally, Annandale Capital LLC bought a new stake in Syndax Pharmaceuticals during the 3rd quarter valued at $67,000.

Syndax Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ:SNDX opened at $20.79 on Monday. The company has a 50 day moving average of $22.74 and a 200 day moving average of $19.49. The stock has a market cap of $1.77 billion, a P/E ratio of -7.02 and a beta of 1.03. Syndax Pharmaceuticals has a 12 month low of $11.22 and a 12 month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same quarter in the prior year, the firm earned ($0.62) EPS. On average, equities analysts forecast that Syndax Pharmaceuticals will post -3.7 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).